Washing contaminated hospital bedsheets in a commercial washing machine with industrial detergent at high disinfecting temperatures failed to remove all traces of Clostridium difficile (C. difficile), a bacteria that causes infectious diarrhoea, suggesting that linens could be a source of infection among patients and even other hospitals, according to a study published.
"The findings of this study may explain some sporadic outbreaks of C. difficile infections in hospitals from unknown sources, however, further research is required in order to establish the true burden of hospital bedsheets in such outbreaks," said Katie Laird, PhD, Head of the Infectious Disease Research Group, School of Pharmacy, De Montfort University, Leicester, United Kingdom and lead author of the study. "Future research will assess the parameters required to remove C. difficile spores from textiles during the laundry process."
Researchers inoculated swatches of cotton sheets with C. difficile. The swatches were then laundered with sterile uncontaminated pieces of fabric using one of two different methods — either in a simulated industrial washing cycle using a washer extractor with and without detergent or naturally contaminated linens from the beds of patients with C. difficile infection were put through a full commercial laundry where they were washed in a washer extractor (infected linen wash) with industrial detergent, pressed, dried, and finished according to current the National Health Service in the United Kingdom’s healthcare laundry policy (Health Technical Memorandum 01-04 Decontamination of Linen for Health and Social Care (2016). Researchers measured the levels of contamination before and after washing.
Both the simulated and the commercial laundering via a washer extractor process failed to meet microbiological standards of containing no disease-causing bacteria, the study found. The full process reduced C. difficile spore count by only 40 percent, and this process resulted in bacteria from the contaminated sheets being transferred to the uncontaminated sheets after washing.
Researchers concluded that thermal disinfection conditions currently required by the UK National Health System are inadequate for the decontamination of C. difficile spores. There may be potential to spread C. difficile back into the hospital environment as linens could be a source for outbreaks at other healthcare facilities through businesses that collect, launder and redistribute rented linens to multiple hospitals and care facilities, as is the case at NHS facilities.
SHEA
https://tinyurl.com/yxh9aa8j
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:52Infectious diarrhoea spores survive high temperatures of hospital laundering
Thirona, a Dutch start-up company specialising in AI to analyse medical images, is offering one of their products for free to medical imaging specialists in an effort to combat the COVID-19 pandemic. International Hospital speaks to Dr Eva van Rikxoort, the Managing Director and founder of Thirona, about the company and its products. International Hospital: Thirona is a Dutch company established in 2014. Can you give our readers a bit of background about the company? Eva van Rikxoort: Thirona started in 2014 as a spin-off from the Radboud University in Nijmegen. We started with two full-time employees and we have built our company to 25 full-time employees and 20 part-time medical analysists. Together, we developed artificial intelligence software to analyse chest CT scans, chest X-ray images and retina images. Healthcare specialists around the world use our AI software for diseases like asthma, COPD, tuberculosis and diabetic retinopathy. IH: What led you to set it up? EVR: I was doing research on chest CT analysis at the Radboud University with my co-founder Prof. Bram van Ginneken. We saw that there was a gap between research that was being done on potential clinical solutions and putting those into clinical practice; Thirona was founded with the vision to bridge that gap. IH: What products did you have at that time? EVR: We started with two launching customers for one solution – our AI solution for chest CT analysis. IH: Where does the name Thirona come from? EVR: The name Thirona comes from the Celtic goddess named Thirona, worshipped for healing. Although more commonly spelled as ‘Sirona’ in the Latin alphabet, the spelling Thirona was chosen to reflect our roots in thoracic image analysis. IH: Delft Imaging appears to be part of Thirona. Can you tell us a bit more about Delft Imaging and the relationship between Thirona and Delft Imaging? EVR: Technically, Thirona and Delft Imaging are separate companies, although we collaborate extensively and practically work together as sister companies. Where Thirona specialises in artificial intelligence software for medical imaging, Delft Imaging specialises in diagnostic innovations that can be used in developing countries. For example, our AI solution for chest X-ray analysis (CAD4TB) is developed by Thirona and distributed by Delft Imaging. IH: Can you tell us briefly about your key products and where they are being used? EVR: We essentially offer three categories of products. AI software for chest CT analysis focusing on COPD and asthma, called LungQ; AI software for X-ray analysis – focusing on tuberculosis, called CAD4TB; and AI software for the analysis of retinal images – focusing on DR, AMD and Glaucoma, called RetCAD. LungQ allows for the quantification of chest CTs and is used for patient monitoring, treatment planning and clinical trial analysis.It is mostly used across the United States and European Union. CAD4TB is used in 40 countries around the world and has screened more than 6 million people for tuberculosis. RetCAD is being rolled out across Europe and Asia. IH: If we look at how the company has grown over the past 5-6 years — can you explain what has been the driving force behind the growth? EVR: As a spin-off of the Radboud University, our company (and our solutions) is rooted in science. Every software product we develop is thoroughly validated (through 150+ publications to date) and that level of validation drives our growth, I believe; our customers know the type of quality we aim to offer. IH: What guided your research and development? In other words, why did you take the product development route you have taken? EVR: We are a demand-driven organisation. Meaning, we develop and work on where our customers and partners have needs to be supported. That has led us on the route we have been on for the past sevearl years. IH: What are the main challenges have you faced and how have you overcome them? EVR: One of the main challenges was keeping the same culture in the company during the growth from a small team of a few people with similar backgrounds to a larger more diverse team. We did this by installing a management team structure. By making it a focus for each team allowed us to overcome any difficulties. IH: Most recently, you are offering a free AI-powered COVID-19 tool – the CAD4COVID-Xray. I understand it has been developed on the back of your successful TB-screening AI tool, CAD4TB. Can you explain how the CAD4TB tool works and how you adapted it for COVID-19 screening. EVR: Yes, we developed two AI-powered COVID-19 tools actually: one for chest X-ray analysis and one for chest CT. Both have been built on the technical foundation of our existing and proven CAD4TB and LungQ solutions. Because there were underlying algorithms already in place, we were able to rapidly pivot these for the detection of COVID-19. IH: How will this tool help healthcare facilities and COVID-19 patients? EVR: CAD4COVID-XRay and CAD4COVID-CT automatically detect COVID-19 related abnormalities and thereby help with triage before any follow-up testing, like RT-PCR. This helps to reduce the workload of healthcare personnel and alleviate the burden on RT-PCR tests. Furthermore, both solutions show the percentage of affected lung tissue, thereby helping to track disease progress and recovery. IH: How has the AI tool been validated? Has it been approved for use in Europe? In which other countries / regions has it been approved? EVR: We have done several studies for both solutions (a publication on CAD4COVID-XRay was recently published in Radiology), through which we were able to prove that the software performs on par with expert human readers. For both solutions we have applied for class IIa CE certification, which we expect to receive soon. IH: Are the CAD4COVID tools specific to certain platforms? EVR: Both solutions are system agnostic. They process DICOM images which can be from any type of system. IH: Are you receiving many requests for the CAD4COVID-Xray AI tool? EVR: The response has been tremendous, which is probably also because we made the software available free-of-charge. CAD4COVIDXRay was launched first (March 31st) and has since been made available to 30+ healthcare facilities across more than 20 countries. We are especially focusing on resource-constrained settings (mostly in developing countries) because in those settings CT often has limited availability, making X-ray all the more important. CAD4COVID-CT was launched a month later and is available at 15+ facilities across 10 countries. We are also integrating it in several platforms through collaborations with partner companies like Smart Reporting. IH: Why are you offering it for free? EVR: We knew that for CAD4COVID to have the biggest impact during the pandemic and provide the most support to healthcare specialists globally, we needed to roll it out rapidly. In order to do that, we wanted to avoid as many hurdles as possible that could cause a delay in facilities being able to use the software. We believe cost is a big factor in that. That’s why we, supported by several organisations, have made it available to use free-of-charge. IH: Can it be shared easily with healthcare facilities that want to use it? EVR: Yes, people can fill in a form on www.delft.care/cad4covid (for CAD4COVID-XRay) and www.thirona.eu/cad4covid (for CAD4COVID-CT) and our team will reach out to them to help them set it up for their facility. IH: Is any training required to use the CAD4COVID tools? EVR: The tool is designed to be very intuitive, but we have developed an onboarding tool to guide new users on how to use the software effectively. IH: Lastly, what’s in the pipeline for Thirona and how do you envisage development of the field of AI in medical imaging? EVR: We are quickly expanding into other areas like cystic fibrosis on chest CT analysis, silicosis on chest X-ray analysis and cataract on retinal images. I believe that AI still has to prove itself in many settings, for many different use cases, but that it will become more and more accepted over time, and we already see this happening at incredible speed. In time, AI will leverage the efforts of our healthcare specialists, helping them to diagnose and determine treatment planning quicker, more effectively and reduce their workload in the meantime.
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:31Thirona, taking AI from spin-off to 40 countries in 6 years
The German Federal Government asked domestic vehicle manufacturers to produce medical equipment, such as masks and ventilators, to help fight Covid-19.
In a statement, the Volkswagen Group announced 20 March it will be providing about 200,000 category FFP-2 and FFP-3 protective face masks for public health protection in the near future. The donation is being made in close cooperation with Federal Minister of Health Jens Spahn.
A spokesperson said the company has more than 125 industrial 3-D printers which could be repurposed to make respirators or other necessary devices, once they receive the required info.
Kathrin Schnurr, spokesperson for Daimler AG Human Resources and External Affairs Communications told International Hospital: “We have inquiries from the medical technology sector. We are currently examining how we can contribute, for example by providing 3D printers or our production expertise.
“In addition, we are in constant communication with the authorities about how and where we can help, for example to sustain the supply infrastructure.”
This follows a trend across Europe as companies unrelated to the medical-device industry offer to retool factories to help make equipment to combat the shortage of devices such as respirators and face masks.
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:38Vehicle manufacturers retool to help medical device industry cope with demand
An observational study conducted in a French hospital showed that human contact was responsible for 90 percent of the spread of one species of antibiotic-resistant bacteria to new patients, but less than 60 percent of the spread of a different species. Audrey Duval of the Versailles Saint Quentin University and Institut Pasteur in Paris, France, and colleagues present these findings. People treated in hospitals and other healthcare settings are increasingly at risk of infection with multidrug-resistant bacteria. Many of these microbes produce enzymes called extended-spectrum β-lactamases (ESBLs), which make them resistant to antibiotics. Understanding how ESBL bacteria spread from person to person is key to developing effective prevention strategies. In the new study, Duval and colleagues distributed wearable sensors to hundreds of patients and healthcare workers in a French hospital. Equipped with RFID tags, the sensors allowed the researchers to track patterns of human contact between patients over an eight-week period. Meanwhile, they systematically screened patients for ESBL-producing Escherichia coli and Klebsiella pneumonia. “By combining digital epidemiology and rapid microbiological diagnostic tools, we may be entering a new era to understand and control the risk of hospital-acquired infection with multidrug-resistant bacteria,” Duval says. An observational study conducted in a French hospital showed that human contact was responsible for 90 percent of the spread of one species of antibiotic-resistant bacteria to new patients, but less than 60 percent of the spread of a different species. Audrey Duval of the Versailles Saint Quentin University and Institut Pasteur in Paris, France, and colleagues present these findings in PLOS Computational Biology. People treated in hospitals and other healthcare settings are increasingly at risk of infection with multidrug-resistant bacteria. Many of these microbes produce enzymes called extended-spectrum β-lactamase (ESBLs), which make them resistant to antibiotics. Understanding how ESBL bacteria spread from person to person is key to developing effective prevention strategies. The scientists found that 90 percent of the spread of ESBL K. pneumonia to new patients could be explained by direct or indirect contact with patients who had the same bacteria within the previous eight weeks; this figure was less than 60 percent for ESBL E. Coli. The findings suggest that contact-prevention strategies — primarily hand hygiene — can be very efficient in limiting transmission of ESBL K. pneumonia. However, additional measures, such as environmental decontamination or using antibiotics more appropriately, may be necessary to prevent spread of ESBL E. Coli. The researchers suggest that the same kind of wearable-sensor analysis could be extended to other multidrug-resistant species. Investigation of more detailed genomic data could further illuminate how ESBL-producing bacteria spread. “By combining digital epidemiology and rapid microbiological diagnostic tools, we may be entering a new era to understand and control the risk of hospital-acquired infection with multidrug-resistant bacteria,” Duval says.
ScienceDailyhttps://tinyurl.com/yxbspjca
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:46Human contact plays role in spread of some hospital infections, but not others
For the benefit of healthcare professionals, medical researchers and the public, Elsevier has created a Novel Coronavirus Information Center with free information in English and Mandarin on the novel coronavirus 2019-nCoV.
The information center on Elsevier Connect, the company’s public news and information website, brings together relevant content from Elsevier’s medical journals, textbooks, clinical experts and information solutions, along with resources from other information providers and major health organizations.
Also available is information typically used by practicing nurses and doctors, plus resources designed specifically for patients and their families.
“As a member of the research and health community, we want to support healthcare professionals, clinical researchers and policy makers in understanding how this new virus works, and so we have brought together the best available information in this free, one-stop information centre,” said John Danaher, MD, President, Global Clinical Solutions, Elsevier. “This site aligns with Elsevier’s commitment to provide free access to key medical and scientific research and information for patients and their caregivers.”
Elsevier’s Novel Coronavirus Information Center is curated by a group of clinicians and other experts at Elsevier, and will be updated frequently with the most current research and evidence-based information available.
The information centre on Elsevier Connect will be updated continuously. The site also links to other authoritative resources, including the US Centers for Disease Control and Prevention (CDC) and the WHO. Sites for health authorities in other affected countries are also listed.
Visit Elsevier’s Novel Coronavirus Information Center — https://www.elsevier.com/connect/coronavirus-information-center
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:34Elsevier creates free Covid-19 information centre
GAMBICA is the Trade Association for Instrumentation, Control, Automation and Laboratory Technology in the UK. Our insight and influence help our members to be more competitive by increasing their knowledge and impact. Together we remove barriers and maximise the market potential in our industry. GAMBICA members are active in the following sectors: • Industrial automation products and systems • Process instrumentation and control • Laboratory technology • Test and measurement equipment for electrical and electronics industries
www.gambica.org.uk
Medica booth # 1G01-3
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:41GAMBICA at Medica
A new study by biomedical engineering researchers at the University of Arkansas could significantly improve methods for detecting and diagnosing congenital heart disease in infants and small children.
The researchers, collaborating with cardiologists at Arkansas Children’s Hospital in Little Rock, tested a new ultrasound technology called vector flow imaging for the first time on paediatric patients to create detailed images of the internal structure and blood flow of the babies’ hearts. The images can be still or moving, and can be taken from any angle.
“Vector flow imaging technology is not yet possible in adults, but we have demonstrated that it is feasible in paediatric patients,” said Morten Jensen, associate professor of biomedical engineering at the U of A. “Our group demonstrated that this commercially available technology can be used as a bedside imaging method, providing advanced detail of blood flow patterns within cardiac chambers, across valves and in the great arteries.”
Roughly 1 percent of all babies are born with some type of congenital heart defect. Fortunately, the majority of these defects will never have any significant impact as the child grows into adulthood and old age. Paediatric cardiologists detect and diagnose congenital heart disease through multiple processes, including echocardiography. This imaging method is based on ultrasound and assesses the overall health of the heart, including valves and muscle contraction.
Although ultrasound provides essential information about cardiac valve function in babies and small children, it has critical limitations. It cannot accurately obtain details of blood flow within the heart. This is due primarily to the inability to align the ultrasound beam with blood-flow direction.
Using a BK5000 Ultrasound machine with built-in vector flow imaging, the researchers performed successful tests on two pigs, one with normal cardiac anatomy and one with congenital heart disease due to a narrow pulmonary valve and a hole within the heart. The researchers then compared the vector flow images to direct examination of the pigs’ hearts.
The researchers subsequently used the imaging system to take cardiac images of two three-month-old babies, one with a healthy, structurally normal heart and one with congenital heart disease because of an abnormally narrow aorta. With both patients, the technology enabled total transthoracic imaging of tissue and blood flow at a depth of 6.5 centimetres. Abnormal flow and detailed cardiac anomalies were clearly observed in the patient with congenital heart disease.
All procedures, both animal and human, were performed at Arkansas Children’s Hospital with assistance from Dr. Elijah Bolin, pediatric cardiologist at UAMS.
“We are still getting used to having this great, new information readily available, and we’re excited about the future in both research and direct clinical advancements,” Bolin said.
“This technology will increase our ability to provide the best possible bedside diagnosis and greatly enhances our understanding of what is happening in hearts with complex abnormalities,” Stanford’s Collins said.
University of Arkansas
https://tinyurl.com/y47ac996
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:49Researchers test new imaging method for first time on human patients
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:36Telehealth comes of age
Infants born to women exposed to high levels of air pollution in the week before delivery are more likely to be admitted to a newborn intensive care unit (NICU), suggests an analysis by researchers at the National Institutes of Health. Depending on the type of pollution, chances for NICU admission increased from about 4% to as much as 147%, compared to infants whose mothers did not encounter high levels of air pollution during the week before delivery. The study was led by Pauline Mendola, Ph.D., of the Epidemiology Branch at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development.
“Short-term exposure to most types of air pollutants may increase the risk for NICU admission,” Dr. Mendola said. “If our findings are confirmed, they suggest that pregnant women may want to consider limiting their time outdoors when air quality advisories indicate unhealthy conditions.”
Previous studies have linked elevated levels of certain kinds of air pollutants to higher risks for gestational diabetes and preeclampsia, a blood pressure disorder of pregnancy. Earlier research also has shown that infants born to women exposed to high levels of air pollutants are at risk for preterm birth, of being small for their gestational age at birth and of growing more slowly than normal in the uterus. Given these associations, the study authors sought to determine whether prenatal exposure to air pollution might increase the chance for NICU admission.
Researchers analysed data from the Consortium on Safe Labor, which compiled information on more than 223,000 births at 12 clinical sites in the United States from 2002 to 2008. They linked records from more than 27,000 NICU admissions to data modified from the Community Multiscale Air Quality Modeling System, which estimates environmental pollution concentrations in the United States. Researchers matched air quality data in the area where each birth occurred to the week before delivery, the day before delivery and the day of delivery. They then compared these time intervals to air quality data two weeks before delivery and two weeks after delivery to identify risk of NICU admission associated with pollution levels.
The researchers also examined the odds of NICU admission associated with high concentrations of particulate matter (pollution particles) less than 2.5 microns in diameter (PM2.5). These types of particles originate from various sources, among them diesel and petrol engines, power plants, landfills, sewage facilities and industrial processes. Exposure to high concentrations of organic compounds in the air was associated with a 147% increase in risk of NICU admission. Elemental carbon and ammonium ions presented similar increases in risk (35% and 37%, respectively), while exposure to nitrate compounds was associated with a 16% higher risk of NICU admission.
Chances of NICU admission increased significantly with exposures to traffic-related pollutants on the day before and the day of delivery, compared to the week before delivery: 4% and 3%, respectively, for an approximately 300 parts per million (ppm) increase in carbon monoxide; 13% and 9% for an approximately 26 ppm increase in nitrogen dioxide; and 6% and 3% for an approximately 3 ppm increase in sulphur dioxide.
Researchers do not know why exposure to air pollution might increase the chances for NICU admission. They theorize, however, that pollutants increase inflammation, leading to impaired blood vessel growth, particularly in the placenta, which supplies oxygen and nutrients to the developing fetus.
Eunice Kennedy Shriver National Institute of Child Health and Human Developmenthttps://tinyurl.com/y3flll6e
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:43Study links air pollution to increase in newborn intensive care admissions
Due to overwhelming demand, entry submissions for the 2019 International Hospital Federation (IHF) Awards has just been extended to 3rd June. Hospitals and health service providers can still nominate their outstanding and innovative projects and programs.
The IHF Awards Committee announced that the extension of the deadline of entries is to give more organizations an opportunity to nominate exemplary programs that deserve international recognition.
There are four categories in total:
1. IHF/Dr Kwang Tae Kim Grand Award
2. IHF/Bionexo Excellence Award for Corporate Social Responsibility
3. IHF/EOH Excellence Award for Leadership and Management in Healthcare
4. IHF/Austco Excellence Award for Quality & Safety and Patient-centered Care
The Awards is open to all public and private healthcare provider organizations. The submission process is simple and at no cost. Interested organizations only need to create an account in the IHF Awards website to accomplish the entry form.
Winners will be awarded in front of industry peers at the Awards Ceremony during the 43rd IHF World Hospital Congress in Muscat, Oman in November.
The 2019 International Hospital Federation (IHF) Awards is sponsored by Dr Kwang Tae Kim, Austco, Bionexo, and EOH.
https://congress.ihf-fih.org/ihf_awards
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:35:292020-08-26 14:35:52International Hospital Federation Awards deadline extended to 3rd June
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.